



Zolgensma (onasemnogene abeparvovec-xioi) Medication Precertification Request

Aetna Precertification Notification
 503 Sunport Lane, Orlando, FL 32809
Phone: 1-866-752-7021
FAX: 1-888-267-3277

Page 1 of 2

(All fields must be completed and legible for Precertification Review)

For Medicare Advantage Part B:
Phone: 1-866-503-0857
FAX: 1-844-268-7263

Please indicate: Start of treatment: Start date ____ / ____ / ____
 Continuation of therapy, Date of last treatment ____ / ____ / ____

Precertification Requested By: _____ **Phone:** _____ **Fax:** _____

A. PATIENT INFORMATION

First Name:		Last Name:		DOB:	
Address:		City:		State:	ZIP:
Home Phone:	Work Phone:	Cell Phone:		Email:	
Patient Current Weight: _____ lbs or _____ kgs		Patient Height: _____ inches or _____ cms		Allergies:	

B. INSURANCE INFORMATION

Aetna Member ID #: _____	Does patient have other coverage? <input type="checkbox"/> Yes <input type="checkbox"/> No
Group #: _____	If yes, provide ID#: _____ Carrier Name: _____
Insured: _____	Insured: _____
Medicare: <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, provide ID #: _____	Medicaid: <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, provide ID #: _____

C. PRESCRIBER INFORMATION

First Name:		Last Name:		(Check One): <input type="checkbox"/> M.D. <input type="checkbox"/> D.O. <input type="checkbox"/> N.P. <input type="checkbox"/> P.A.	
Address:		City:		State:	ZIP:
Phone:	Fax:	St Lic #:	NPI #:	DEA #:	UPIN:
Provider Email:		Office Contact Name:		Phone:	
Specialty (Check one): <input type="checkbox"/> Neurologist <input type="checkbox"/> Pediatrician <input type="checkbox"/> Other: _____					

D. DISPENSING PROVIDER/ADMINISTRATION INFORMATION

Place of Administration: <input type="checkbox"/> Self-administered <input type="checkbox"/> Physician's Office <input type="checkbox"/> Outpatient Infusion Center Phone: _____ Center Name: _____ <input type="checkbox"/> Home Infusion Center Phone: _____ Agency Name: _____ <input type="checkbox"/> Administration code(s) (CPT): _____ Address: _____	Dispensing Provider/Pharmacy: <i>Patient Selected choice</i> <input type="checkbox"/> Physician's Office <input type="checkbox"/> Retail Pharmacy <input type="checkbox"/> Specialty Pharmacy <input type="checkbox"/> Other _____ Name: _____ Address: _____ Phone: _____ Fax: _____ TIN: _____ PIN: _____
---	--

E. PRODUCT INFORMATION

Request is for: Zolgensma (onasemnogene abeparvovec-xioi)
Dose: _____ **Frequency:** _____

F. DIAGNOSIS INFORMATION - Please indicate primary ICD code and specify any other where applicable.

Primary ICD Code: _____ **Secondary ICD Code :** _____ **Other ICD Code:** _____

G. CLINICAL INFORMATION - Required clinical information must be completed in its entirety for all precertification requests.

For All Requests (Clinical documentation must be submitted with request):

Yes No Has the patient received Zolgensma (onasemnogene abeparvovec-xioi) in the past?
 Yes No Does the patient have a genetically confirmed diagnosis of spinal muscular atrophy (SMA)?
 Yes No Is there documentation of bi-allelic mutations in the survival motor neuron 1 (SMN1) gene?
 Yes No Please select: SMN1 deletions SMN1 point mutations
 Please enter the date genetic testing was completed: Date: ____ / ____ / ____
 Yes No Does the patient have an anti-adenovirus 9 (AAV9) antibody titer < 1:50 as determined by Enzyme-linked Immunosorbent Assay (ELISA) binding immunoassay?
 Yes No Does the patient have any of the following indicators of advanced disease?
 The patient does not have advanced disease
 Please select: Complete paralysis of limbs Invasive ventilatory support (tracheostomy) Respiratory assistance for 16 or more hours per day (including non-invasive respiratory support) continuously for 14 or more days in the absence of acute reversible illness (excluding perioperative ventilation)
 Other indicators of advanced disease-Please explain: _____
 Yes No Is the medication prescribed by or in consultation with a physician who specializes in treatment of SMA?
 Yes No Is the patient currently being treated with Spinraza (nusinersen)?
 Yes No Will Spinraza (nusinersen) be discontinued prior to administration of Zolgensma (onasemnogene abeparvovec-xioi)?
 Please provide the name of the gene therapy designated center Zolgensma (onasemnogene abeparvovec-xioi) will be administered at:
 Name: _____

Continued on next page



**Zolgensma (onasemnogene
abeparvovec-xioi) Medication
Precertification Request**

Page 2 of 2

(All fields must be completed and legible for Precertification Review)

Aetna Precertification Notification
503 Sunport Lane, Orlando, FL 32809
Phone: 1-866-752-7021
FAX: 1-888-267-3277

For Medicare Advantage Part B:
Phone: 1-866-503-0857
FAX: 1-844-268-7263

Patient First Name	Patient Last Name	Patient Phone	Patient DOB
--------------------	-------------------	---------------	-------------

H. ACKNOWLEDGEMENT

Request Completed By (Signature Required): _____ **Date:** ____ / ____ / ____

Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties.

The plan may request additional information or clarification, if needed, to evaluate requests.